Multidrug Resistance in Acute Myeloid Leukemia: Potential New Therapeutics

In acute myeloid leukemias (AMLs), multidrug resistance (MDR) is frequently, but not always, caused by the MDR1 gene product, a 170- to 180-kDa glycoprotein known as P-glycoprotein (Pgp) or human MDR1 protein (1). It is characterized by broad resistance to several structurally, chemically, and pharmacologically distinct chemotherapeutic compounds. Many theories explain how Pgp affects MDR, including the “drug pump” model, in which Pgp hydrolyzes adenosine triphosphate to actively pump drugs out of the cell (2,3). As many MDR cells have been found to have increased intracellular pH and decreased plasma membrane potentials, another explanation of the MDR mechanism of Pgp is the altered-partition model. This model takes into account how the alterations in intracellular pH and membrane potential that accompany the overexpression of Pgp indirectly affect the partitioning of the drugs, but Pgp does not directly pump the drugs out of the cell (4–6). Other drug-resistance proteins, which are associated with hematologic cancers that use similar mechanisms, include the MDR-associated protein, the lung resistance protein, and the breast cancer resistance protein (7).

Many investigators working to improve cancer therapy have tried to use various immunologic approaches to killing cancer cells because such approaches might circumvent chemotherapeutic drug resistance. One of the assumptions of an immunologic approach is that cells that are resistant to chemotherapeutics should not be cross-resistant to immunotherapy because the mechanisms of action are so widely different. Unfortunately, several groups have shown that MDR cells seem to be resistant to several forms of immunologic therapies, including complement-mediated cytotoxicity (5,6), immunotoxin, gelonin attached to monoclonal antibodies (mAbs) (8), interleukin 2 (9), and drug immunonjugates (10–12).

Another immunologic treatment is the use of mAbs to deliver radioisotopes directly to the tumor cells. At the present time, the use of radiolabeled antibodies in the treatment of AML with Pgp expression has not been well studied, if at all. In this issue of The Journal of Nuclear Medicine, Kersemans et al. (13) use a strategy to overcome MDR using mAbs that have been labeled with 111In modified with a nuclear localizing sequence (NLS). They showed that the addition of the peptide sequence CGYGPKKKRKVGG, which contains the NLS PKKKRKV of SV-40 large T-antigens, allowed the antibody to be internalized and to translocate to the nucleus. Once in the nucleus, Auger electrons from the 111In were cytotoxic to the parental HL60 cell line and drug-resistant (mitoxantrone-insensitive) HL60-MX-1 cell line and to the primary AML specimens that were expressing a diversity of MDR phenotypes. These results suggest that 111In anti-CD33 mAbs that are modified with an NLS may be a new treatment for patients who have drug-resistant myeloid leukemias.

Although there have been significant advances in the treatment of AML, only 20%–30% of these patients reach long-term disease-free survival (14). The addition of Pgp expression predicts an even poorer prognosis in the elderly, those patients who have relapsed, and patients with secondary AML (11,15).

When considering radioimmunotherapy for the treatment of any type of cancer, one must keep in mind three important factors: the target tumor, isotope, and antibody (16). Because leukemias are easily accessible and have well-defined differentiation antigens, they are ideal for the use of radiolabeled antibodies (17). AML is characterized by the expression of CD13, CD15, CD33, and CD117 (18). CD33 is a 67-kDa cell-surface glycoprotein found on myeloid leukemia and on committed myelomonocytic and erythroid progenitor cells. It is not found on lymphoid, nonhematopoietic, or mature myeloid cells, making CD33 a prime target for antibody binding (19,20).

Different isotopes have been attached to antibodies based on their half-life and the type of particle they emit. For single-cell kill, with the least cytotoxicity to normal cells, the ideal isotope emission should have a path length that is the same as that of the target cells (21). 90Y and 131I emit β-particles, which have a relatively long range and a low linear-energy transfer. Unfortunately, these properties make β-particles an excellent choice for solid tumors but not for hematologic cancers, in which antibodies cannot bind to all the tumors cells at sufficient levels (21). This long particle range results in the irradiation of target tumor cells as well as surrounding cells, causing normal cells to be killed. Alpha-particles, on the other hand, have a shorter range...
(about the size range of 3–5 times that of the target cells) than β-particles and a much higher linear energy transfer. Only one α-particle is needed to cross the nucleus to induce cell death by causing double-strand breaks in the DNA, making α-particles more efficient than β-particles at killing a single cell. The shorter range of α-particles is beneficial in 2 ways. First, nonspecific cytotoxicity to nearby healthy cells should be reduced, and second, because the path length of α-particles is shorter, they would be an effective single-cell killer (22). Auger electrons have a high-energy transfer and an even smaller path length than do α-particles, making Auger electrons also suitable for the treatment of hematologic cancers. High antigen densities are essential because a large number of decays is vital for strong cytotoxicity (23). The dose, meaning what kills the cells, is dependent on the energy of the particle and the half-life. Unlike α- and β-radiation, Auger emitters need to be attached to the individual tumor cells and enter the nucleus. Optimum results with Auger electron emitters were seen when they were bound to the DNA, causing double-stand breaks (24).

In the study by Kersemans et al. (13), the authors were able to specifically target the nucleus of the HL-60 and HL-60-MX-1 cells by the addition of the NLS onto the antibodies, increasing the nuclear localization efficiency on high levels of antibody binding. The results demonstrated in the article by Kersemans et al. (13) show that there may be a treatment to overcome MDR in AML and perhaps other types of hematologic cancers.

Jeffrey H. Weisburg
Yeshiva University
New York, New York

REFERENCES


**Erratum**

In the article “SPECT/CT,” by Buck et al. (*J Nucl Med.* 2008;49:1305–1319), the legends of Figures 1, 5, and 6 contain errors. In the legend of Figure 1, “99mTc-iodobenzamide” should be “123I-ioflupane (DaTSCAN [GE Healthcare]).” In the legend of Figure 5, panel B is described as a 99mTc-MIBI scan but is in fact a 99mTc-pertechnetate scan. In the legend of Figure 6, “99mTc-MIBG” should be “123I-MIBG.” The authors regret the errors.
Multidrug Resistance in Acute Myeloid Leukemia: Potential New Therapeutics

Jeffrey H. Weisburg

Published online: August 14, 2008.
Doi: 10.2967/jnumed.107.050153

This article and updated information are available at:
http://jnm.snmjournals.org/content/49/9/1405

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml